...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American Journal of Cardiology >Effects of Atorvastatin (80 mg) Therapy on Quantity of Epicardial Adipose Tissue in Patients Undergoing Pulmonary Vein Isolation for Atrial Fibrillation
【24h】

Effects of Atorvastatin (80 mg) Therapy on Quantity of Epicardial Adipose Tissue in Patients Undergoing Pulmonary Vein Isolation for Atrial Fibrillation

机译：阿托伐他汀（80毫克）治疗对肺静脉隔离房颤患者心外膜脂肪组织数量的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Epicardial adipose tissue (EAT) has been recognized as a sensitive marker of cardiometabolic risk. Recent evidence suggests efficacy of long-term statin therapy in reducing EAT in patients with coronary artery disease. Whether short-term statin therapy is associated with changes in the volume of EAT is currently unknown. A cohort of patients with atrial fibrillation who underwent pulmonary vein isolation were randomized to receive either 80 mg/day of atorvastatin (n = 38, 32 men, age 56 11 years) or placebo (n = 41, 33 men, age 56 +/- 10 years) for a 3-month period. EAT volume was assessed by cardiac computed tomography at baseline and at follow-up. Patients randomized to statin treatment exhibited a modest but significant decrease in median EAT volume (baseline vs follow-up: 92.3 cm(3) [62.0 to 133.3] vs 86.9 cm(3) [64.1 to 124.8], p < 0.05), whereas median EAT remained unchanged in the placebo group (81.9 cm(3) [55.5 to 110.9] vs 81.3 cm(3) [57.1 to 110.5], p = NS). Changes in median systemic inflammatory markers and lipid profile were also seen with statin treatment: C-reactive protein (2.4 mg/L [0.7 to 3.7] vs 1.1 mg/L [0.5 to 2.7], p < 0.05), total cholesterol (186 mg/dL [162.5 to 201] vs 123 mg/dL [99 to 162.5], p < 0.001), and low-density lipoprotein cholesterol (116 mg/dL [96.5 to 132.5] Vs 56 [40.5 to 81] mg/dL, p < 0.001) diminished, whereas median body mass index did not change (27.8 kg/m(2) [25 to 30] versus 27.6 kg/m(2) [25.7 to 30.5], p = NS). No variations occurred in the placebo group. In conclusion, short-term intensive statin therapy significantly reduced the volume of EAT in patients with atrial fibrillation. (C) 2015 Elsevier Inc. All rights reserved.
机译：心外膜脂肪组织（EAT）被认为是心脏代谢风险的敏感标志。最近的证据表明长期他汀类药物疗法可减少冠状动脉疾病患者的EAT。目前尚不清楚短期他汀类药物疗法是否与EAT量的变化有关。一组接受肺静脉隔离的房颤患者被随机分配接受80毫克/天的阿托伐他汀（n = 38，32男性，年龄56 11岁）或安慰剂（n = 41，33男性，56岁+ / -10年），为期3个月。在基线和随访时通过心脏计算机体层摄影术评估EAT量。随机接受他汀类药物治疗的患者的EAT中位数显示适度但显着降低（基线vs随访：92.3 cm（3）[62.0至133.3] vs 86.9 cm（3）[64.1至124.8]，p <0.05），而安慰剂组的EAT中位数保持不变（81.9 cm（3）[55.5至110.9]与81.​​3 cm（3）[57.1至110.5]，p = NS）。他汀类药物治疗还观察到中位全身炎症标志物和脂质谱的变化：C反应蛋白（2.4 mg / L [0.7至3.7] vs 1.1 mg / L [0.5至2.7]，p <0.05），总胆固醇（186） mg / dL [162.5至201]与123 mg / dL [99至162.5]，p <0.001）和低密度脂蛋白胆固醇（116 mg / dL [96.5至132.5] vs 56 [40.5至81] mg / dL ，p <0.001）减小，而中位体重指数不变（27.8 kg / m（2）[25至30]与27.6 kg / m（2）[25.7至30.5]，p = NS）。安慰剂组无变化。总之，短期强化他汀类药物治疗可显着减少房颤患者的EAT量。 （C）2015 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号